Skip to main content

Hepatic Encephalopathy News

Rates of Tx Retention for Rifaximin Low Despite Benefits for Hepatic Encephalopathy

FRIDAY, Sept. 1, 2023 – Rates of rifaximin treatment retention are low despite the known benefits of rifaximin use for breakthrough hepatic encephalopathy (HE), according to a study published in the...

FDA Approves New Use of Xifaxan for Patients with Liver Disease

SILVER SPRING, Md., March 24 /PRNewswire-USNewswire/ – The U.S. Food and Drug Administration today approved the use of Xifaxan for reduction in the risk of the recurrence of overt hepatic...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related drug support groups

lactulose, Xifaxan, neomycin